- Conditions
- Schizophrenia
- Interventions
- LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo, Standard of Care
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- Olanzapine, Aprepitant
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Interventions
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 6
- States / cities
- Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
- Conditions
- Schizophrenia
- Interventions
- AVE1625, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Schizophrenia
- Interventions
- iloperidone
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- olanzapine, risperidone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Schizophrenia, Psychotic Disorders
- Interventions
- Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
- Conditions
- Headache
- Interventions
- Standard of Care as per attending physician, 5mg rapidly dissolving olanzapine
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
- Interventions
- Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
- Dietary Supplement · Drug · Other
- Lead sponsor
- Corey Hawes
- Other
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Schizophrenia
- Interventions
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
- Other · Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 34
- States / cities
- Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
- Conditions
- Schizophrenia, Schizoaffective Disorders
- Interventions
- olanzapine, amantadine, metformin, zonisamide, Wellness education
- Drug · Behavioral
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
- Conditions
- Schizophrenia
- Interventions
- Ziprasidone, Olanzapine, Placebo Comparator
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Visual Decision Aid and Shared Decision Making Model, Usual Care
- Behavioral
- Lead sponsor
- VA Nebraska Western Iowa Health Care System
- Federal
- Eligibility
- 19 Years to 65 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
- Interventions
- ALKS 3831, Olanzapine
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 16 Years to 40 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 19 more
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Olanzapine, Lu AF35700
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,098 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 49
- States / cities
- Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 36
- States / cities
- Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more
- Conditions
- Schizophrenia
- Interventions
- PF-00184562, Olanzapine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Advanced Cancer
- Interventions
- Olanzapine, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Rochester, Minnesota + 2 more
- Conditions
- Borderline Personality Disorder
- Interventions
- olanzapine
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Negative Symptoms in Schizophrenia
- Interventions
- Roluperidone 64 mg, Olanzapine 10 MG
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey
- Conditions
- Bipolar Depression
- Interventions
- Olanzapine Fluoxetine Combination (OFC), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
- Interventions
- Olanzapine, Placebo Oral Tablet
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 30 Months to 18 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 5
- States / cities
- San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more